NCT00920257 2017-11-13
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
GlaxoSmithKline
Phase 1 Completed
Clinical Trials
3 trialsNCT01138085 2017-11-13
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
GlaxoSmithKline
Phase 1 Completed
NCT01266954 2017-11-09
An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer
GlaxoSmithKline
Phase 1 Completed